{
    "clinical_study": {
        "@rank": "48848", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have\n      metastatic kidney cancer."
        }, 
        "brief_title": "PS-341 in Treating Patients With Metastatic Kidney Cancer", 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy of PS-341 in patients with metastatic renal cell carcinoma.\n\n        -  Determine the safety of this drug in these patients.\n\n      OUTLINE: This is an open-label study.\n\n      Patients receive PS-341 IV over 3-5 seconds twice weekly for 2 weeks. Treatment repeats\n      every 3 weeks in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed at 2 weeks.\n\n      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed renal cell carcinoma\n\n               -  Metastatic disease\n\n          -  Unidimensionally measurable disease\n\n          -  No brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  ALT/AST no greater than 2.5 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN\n\n        Other:\n\n          -  No pre-existing neuropathy of grade 1 or greater\n\n          -  No other malignancy within the past 5 years, except completely resected basal cell\n             skin cancer, unless treated with potentially curative therapy or at low risk for\n             recurrence\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 4 months after study\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 4 weeks since prior biologic therapy and recovered\n\n          -  No concurrent biologic therapy\n\n        Chemotherapy:\n\n          -  No prior cytotoxic therapy\n\n          -  No concurrent cytotoxic therapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  At least 4 weeks since prior major surgery\n\n        Other:\n\n          -  No other concurrent anticancer therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "June 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00017329", 
            "org_study_id": "CDR0000068678", 
            "secondary_id": [
                "MSKCC-01032", 
                "NCI-3031"
            ]
        }, 
        "intervention": {
            "intervention_name": "bortezomib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "keyword": "stage IV renal cell cancer", 
        "lastchanged_date": "December 13, 2009", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-01032"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Trial of PS341 (NSC 681239) in Patients With Advanced Renal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Beverly Drucker, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00017329"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2009"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}